UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 156

Sortiert nach

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review

PloS one, 2016-02, Vol.11 (2), p.e0149803-e0149803

2016

Link zum Volltext

Verfügbarkeit prüfen

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis

PloS one, 2012-08, Vol.7 (8), p.e44064

2012

Link zum Volltext

Verfügbarkeit prüfen

Warfarin dosing algorithms: A systematic review

British journal of clinical pharmacology, 2021-04, Vol.87 (4), p.1717-1729

2021

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Trial of Genotype-Guided Dosing of Warfarin

The New England journal of medicine, 2013-12, Vol.369 (24), p.2294-2303

2013

Link zum Volltext

Verfügbarkeit prüfen

STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline

PLoS medicine, 2020-09, Vol.17 (9), p.e1003344-e1003344

2020

Link zum Volltext

Verfügbarkeit prüfen

Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study

BMC medicine, 2019-04, Vol.17 (1), p.76-11, Article 76

2019

Link zum Volltext

Verfügbarkeit prüfen

Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population

Clinical infectious diseases, 2013-05, Vol.56 (9), p.1330-1339

2013

Link zum Volltext

Verfügbarkeit prüfen

SurvivalGWAS_SV: software for the analysis of genome-wide association studies of imputed genotypes with "time-to-event" outcomes

BMC bioinformatics, 2017-05, Vol.18 (1), p.265-265, Article 265

2017

Link zum Volltext

Verfügbarkeit prüfen

A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients

Frontiers in pharmacology, 2022-09, Vol.13, p.967082-967082

2022

Link zum Volltext

Verfügbarkeit prüfen

Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease

JHEP reports, 2023-12, Vol.5 (12), p.100896-100896, Article 100896

2023

Link zum Volltext

Verfügbarkeit prüfen

Methodological quality of pharmacogenetic studies: Issues of concern

Statistics in medicine, 2008-12, Vol.27 (30), p.6547-6569

2008

Link zum Volltext

Verfügbarkeit prüfen

Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck

Cell death & disease, 2019-12, Vol.10 (12), p.912-10, Article 912

2019

Link zum Volltext

Verfügbarkeit prüfen

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review

Journal of personalized medicine, 2017-01, Vol.7 (1), p.1

2017

Link zum Volltext

Verfügbarkeit prüfen

Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm

CPT: pharmacometrics and systems pharmacology, 2022-01, Vol.11 (1), p.20-29

2022

Link zum Volltext

Verfügbarkeit prüfen

CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis

Systematic reviews, 2018-11, Vol.7 (1), p.204-15, Article 204

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of Genetic Variability in the CYP4F2 , CYP4F11 , and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response

Frontiers in pharmacology, 2017-05, Vol.8, p.323-323

2017

Link zum Volltext

Verfügbarkeit prüfen

Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration

EBioMedicine, 2021-12, Vol.74, p.103728-103728, Article 103728

2021

Link zum Volltext

Verfügbarkeit prüfen

Genetic Determinants of Thiazide‐Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances – A Genome‐Wide Evaluation of the UK Biobank

Clinical pharmacology and therapeutics, 2024-06, Vol.115 (6), p.1408-1417

2024

Link zum Volltext

Verfügbarkeit prüfen

A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study

JMIR research protocols, 2023-07, Vol.12, p.e46710-e46710

2023

Link zum Volltext

Verfügbarkeit prüfen

Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome

Journal of clinical lipidology, 2017-01, Vol.11 (1), p.204-214

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

Pharmacogenetics and genomics, 2009-10, Vol.19 (10), p.781-789

2009

Link zum Volltext

Verfügbarkeit prüfen

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

Pharmacogenetics and genomics, 2009-10, Vol.19 (10), p.800-812

2009

Link zum Volltext

Verfügbarkeit prüfen

Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med . 2017, 7 , 1

Journal of personalized medicine, 2018-05, Vol.8 (2), p.17

2018

Link zum Volltext

Verfügbarkeit prüfen

Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7 , 19

Journal of personalized medicine, 2018-05, Vol.8 (2), p.18

2018

Link zum Volltext

Verfügbarkeit prüfen

Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size

Journal of personalized medicine, 2017-12, Vol.7 (4), p.19

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(149)
Mit Volltextzugriff
(137)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis

Warfarin dosing algorithms: A systematic review

A Randomized Trial of Genotype-Guided Dosing of Warfarin

STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline

Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study

Association of Human Leukocyte Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected Population

SurvivalGWAS_SV: software for the analysis of genome-wide association studies of imputed genotypes with "time-to-event" outcomes

A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients

Role of fatty liver index in risk-stratifying comorbid disease outcomes in non-alcoholic fatty liver disease

Methodological quality of pharmacogenetic studies: Issues of concern

Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review

Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm

CYP genetic variants and toxicity related to anti-tubercular agents: a systematic review and meta-analysis

Effect of Genetic Variability in the CYP4F2 , CYP4F11 , and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response

Genome-Wide association between EYA1 and Aspirin-induced peptic ulceration

Genetic Determinants of Thiazide‐Induced Hyperuricemia, Hyperglycemia, and Urinary Electrolyte Disturbances – A Genome‐Wide Evaluation of the UK Biobank

A "Bundle of Care" to Improve Anticoagulation Control in Patients Receiving Warfarin in Uganda and South Africa: Protocol for an Implementation Study

Investigating the prevalence, predictors, and prognosis of suboptimal statin use early after a non-ST elevation acute coronary syndrome

Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

Correction: Antoniou, M.; et al. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J. Pers. Med . 2017, 7 , 1

Correction: Antoniou, M.; et al. Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J. Pers. Med. 2017, 7 , 19

Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size

Suchergebnisse filtern